These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33105016)

  • 1. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
    Almradi A; Hanzel J; Sedano R; Parker CE; Feagan BG; Ma C; Jairath V
    BioDrugs; 2020 Dec; 34(6):713-721. PubMed ID: 33105016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting IL-23 for IBD: Rationale and Progress to Date.
    Vuyyuru SK; Shackelton LM; Hanzel J; Ma C; Jairath V; Feagan BG
    Drugs; 2023 Jul; 83(10):873-891. PubMed ID: 37266801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
    Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
    [No Abstract]   [Full Text] [Related]  

  • 4. The Role of IL-23 Inhibitors in Crohn's Disease.
    Fanizza J; D'Amico F; Lusetti F; Fasulo E; Allocca M; Furfaro F; Zilli A; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S; Fiorino G
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of IL-23: What is in the Pipeline?
    Parigi TL; Iacucci M; Ghosh S
    J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
    Hanžel J; D'Haens GR
    Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
    [No Abstract]   [Full Text] [Related]  

  • 7. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
    Deepak P; Loftus EV
    Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
    Ma C; Panaccione R; Khanna R; Feagan BG; Jairath V
    Best Pract Res Clin Gastroenterol; 2019; 38-39():101604. PubMed ID: 31327402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.
    Noviello D; Mager R; Roda G; Borroni RG; Fiorino G; Vetrano S
    Front Immunol; 2021; 12():611256. PubMed ID: 34079536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced and spontaneous colitis mouse models reveal complex interactions between IL-10 and IL-12/IL-23 pathways.
    Hurtubise R; Audiger C; Dominguez-Punaro MC; Chabot-Roy G; Chognard G; Raymond-Marchand L; Coderre L; Chemtob S; Michnick SW; Rioux JD; Lesage S
    Cytokine; 2019 Sep; 121():154738. PubMed ID: 31158699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on ustekinumab for the treatment of Crohn's disease.
    Leung Y; Panaccione R
    Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
    Wong U; Cross RK
    Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
    Verstockt B; Salas A; Sands BE; Abraham C; Leibovitzh H; Neurath MF; Vande Casteele N;
    Nat Rev Gastroenterol Hepatol; 2023 Jul; 20(7):433-446. PubMed ID: 37069321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.
    Abraham C; Dulai PS; Vermeire S; Sandborn WJ
    Gastroenterology; 2017 Feb; 152(2):374-388.e4. PubMed ID: 27780712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
    Hanzel J; Ma C; Jairath V
    Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalised Medicine with IL-23 Blockers: Myth or Reality?
    Gottlieb ZS; Sands BE
    J Crohns Colitis; 2022 May; 16(Supplement_2):ii73-ii94. PubMed ID: 35553661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.